FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series B / Biotech startups that raised Series B in DACH

Biotech startups that raised Series B in DACH

Updated 16 Nov 2026

Reset
Biotech startups that raised Series B in DACH
One-time CSV
  • 67 funded companies, 40 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-b~dach.csv67 rows × 18 columns
CompanyCityLast roundAmountDate
NovaGo TherapeuticsSchlierenSeries B$29.7M2026-08-31
ComputomicsTübingenSeries B$7.3M2026-08-18
Vaderis TherapeuticsBaselSeries B$152.0M2026-08-11
NVision Quantum TechnologiesUlmSeries B$38.0M2026-05-13
Windward BioBaselSeries B$165.0M2026-05-04
OrbemMunichSeries B$64.6M2026-01-20
ExcivaHeidelbergSeries B$59.4M2026-01-20
GlycoEraWädenswilSeries B$130.0M2025-05-27

8 rows of the CSV in 5 of its 18 columns.

67
Startups
$2.2B
Total raised
8
Funded in the last 12 months
$566.0M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

29 of 67
29 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
NovaGo Therapeutics NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. Biotech Schlieren, Switzerland Series B $29.7M 2026-08-31 $39.7M Kinled Holding, Pureos Bioventures 1 to 10 2015
Computomics Computomics applies artificial intelligence to genomics data to advance agricultural solutions. Artificial intelligence Tübingen, Germany Series B $7.3M 2026-08-18 $10.0M HTGF (High-Tech Gruenderfonds), VentureOut, European Innovation Council +2 11 to 50 2012
Vaderis Therapeutics Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. Biotech Basel, Switzerland Series B $152.0M 2026-08-11 $170.6M Medicxi 11 to 50 2019
NVision Quantum Technologies NVision Quantum Technologies develops quantum-based imaging technology that enhances standard MRI systems. Biotech Ulm, Germany Series B $38.0M 2026-05-13 $155.2M Entrée Capital, European Commission, Playground Global +2 101 to 250 2015
Windward Bio Windward Bio develops monoclonal antibodies for advanced immunological diseases. Biotech Basel, Switzerland Series B $165.0M 2026-05-04 $365.0M Qiming Venture Partners, OrbiMed, Novo Holdings +2 11 to 50 2024
Orbem Orbem provides AI-powered imaging and analytics for non-invasive biological insights. Artificial intelligence Munich, Germany Series B $64.6M 2026-01-20 $106.5M European Innovation Council, Possible Ventures, 83North +1 101 to 250 2019
Exciva Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. Biotech Heidelberg, Germany Series B $59.4M 2026-01-20 $69.8M Andera Partners, LBBW VC, Cure8 Ventures 1 to 10 2015
GlycoEra GlycoEra researches and produces extracellular protein degraders for treating autoimmune diseases. Biotech Wädenswil, Switzerland Series B $130.0M 2025-05-27 $179.3M Sofinnova Partners, Bristol-Myers Squibb, 5AM Ventures +1 11 to 50 2020
Clinomic Clinomic is a medical AI company focused on critical care. Artificial intelligence Aachen, Germany Series B $25.3M 2025-04-08 $54.6M German Federal Ministry of Research, Technology and Space 51 to 100 2019
Noema Pharma Noema Pharma develops therapies that treat disabling symptoms of brain and nervous system conditions. Biotech Basel, Switzerland Series B $147.2M 2024-12-11 $316.5M Polaris Partners, Sofinnova Partners, Invus +2 11 to 50 2019
Qualifyze Qualifyze provides global quality audit and site risk management solutions for life sciences companies. Biotech Frankfurt, Germany Series B $54.0M 2024-09-10 Insight Partners, APX, HV Capital +2 101 to 250 2019
CorFlow Therapeutics CorFlow Therapeutics develops proprietary technologies to diagnose and treat microvascular obstructions. Biotech Baar, Switzerland Series B $48.5M 2024-09-10 $66.1M Innosuisse, Unorthodox Ventures, Panakes Partners +2 11 to 50 2016
iOnctura iOnctura is a clinical-stage biotechnology company developing treatments for cancer. Biotech Geneva, Switzerland Series B $85.7M 2024-06-20 European Innovation Council, M Ventures, VI Partners +2 11 to 50 2017
Hemotune Hemotune develops a therapeutic blood purification platform for treating health conditions. Biotech Schlieren, Switzerland Series B $15.6M 2024-03-25 Venture Kick, Innosuisse, Gebert Rüf Stiftung 11 to 50 2016
Resolve BioSciences Resolve BioSciences conducts biotechnology research in molecular cartography. Biotech Düsseldorf, Germany Series B $71.0M 2022-10-24 $95.0M HTGF (High-Tech Gruenderfonds), EDBI, NRW.BANK +2 51 to 100 2020
Cardior Pharmaceuticals Cardior Pharmaceuticals develops medicines and therapies to treat and prevent heart disease. Biotech Hanover, Germany Series B $75.3M 2021-08-25 HTGF (High-Tech Gruenderfonds), EQT Life Sciences, Bristol-Myers Squibb +2 11 to 50 2016
Topas Therapeutics Topas Therapeutics is a biotechnology company developing products for major unmet medical needs. Biotech Hamburg, Germany Series B $21.4M 2021-07-29 Boehringer Ingelheim Venture Fund, BioMedPartners, Vesalius Biocapital Partners +1 51 to 100 2006
MaxiVAX MaxiVAX is a Swiss clinical-stage biotechnology company. Biotech Geneva, Switzerland Series B $5.0M 2019-11-27 EIC Accelerator 1 to 10 2005
Hemovent Hemovent is an emerging medical device company developing new technology. Biotech Aachen, Germany Series B $5.2M 2019-02-14 $13.5M KfW, NRW.BANK, TechVision Fund +2 1 to 10 2013
Amal Therapeutics Amal Therapeutics SA is a privately held Swiss and German biotech startup spun off from the University of Geneva. Biotech Geneva, Switzerland Series B $32.6M 2018-11-12 HTGF (High-Tech Gruenderfonds), Venture Kick, VI Partners +2 11 to 50 2012
Therachon Therachon is a global biotechnology company developing medicines for rare genetic diseases. Biotech Basel, Switzerland Series B $60.0M 2018-08-09 $100.0M Bpifrance, New Enterprise Associates, OrbiMed +2 1 to 10 2014
Cardiorentis Cardiorentis is a privately owned biopharmaceutical company. Biotech Zug, Switzerland Series B $60.4M 2016-01-10 HealthCare Royalty Partners 1 to 10 2010
Covagen Covagen develops protein-based therapeutics for inflammatory diseases and cancer. Biotech Schlieren, Switzerland Series B $66.1M 2013-12-09 Ventech, Novartis Venture Fund, Andera Partners +2 11 to 50 2007
Mind-NRG Mind-NRG develops peptidic neurotrophic factors for psychiatric and neurologic diseases. Biotech Geneva, Switzerland Series B $7.9M 2013-09-04 Index Ventures, Limburgse Reconversie Maatschappij 1 to 10 2010
Subitec Subitec produces microalgae biomass substances for the cosmetics and food additives industries. Biotech Stuttgart, Germany Series B $5.5M 2012-07-16 HTGF (High-Tech Gruenderfonds), KfW, eCAPITAL ENTREPRENEURIAL PARTNERS +1 11 to 50 2000
Okairos Okairos develops genetic T-cell vaccines, including candidates targeting hepatitis C virus. Biotech Basel, Switzerland Series B $20.5M 2010-09-14 $30.1M EQT Life Sciences, Versant Ventures, Novartis Venture Fund +2 1 to 10 2007
ESBATech ESBATech develops fully human antibody fragments for therapeutic applications using the single-chain antibody framework. Biotech Schlieren, Switzerland Series B $22.0M 2008-08-07 Novartis Venture Fund, VI Partners, SV Health Investors +2 51 to 100 1998
Vivendy Therapeutics Vivendy Therapeutics develops enzyme replacement therapies. Biotech Basel, Switzerland Series B $30.5M 2008-06-23 EQT Life Sciences, BioMedPartners, TVM Capital +1 11 to 50 2006
PregLem PregLem is a Swiss biopharmaceutical company that develops and commercializes new drugs. Biotech Geneva, Switzerland Series B $32.2M 2007-12-04 $58.2M Sofinnova Partners, Sofinnova Investments, MVM Life Science Partners +1 11 to 50 2006

Table 1. Biotech startups that raised Series B in DACH: the 29 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 67.

Largest rounds

Last 12 months
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 Windward Bio Windward Bio develops monoclonal antibodies for advanced immunological diseases. Biotech Basel, Switzerland Series B $165.0M 2026-05-04 $365.0M Qiming Venture Partners, OrbiMed, Novo Holdings +2 11 to 50 2024
2 Vaderis Therapeutics Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. Biotech Basel, Switzerland Series B $152.0M 2026-08-11 $170.6M Medicxi 11 to 50 2019
3 Orbem Orbem provides AI-powered imaging and analytics for non-invasive biological insights. Artificial intelligence Munich, Germany Series B $64.6M 2026-01-20 $106.5M European Innovation Council, Possible Ventures, 83North +1 101 to 250 2019
4 Exciva Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. Biotech Heidelberg, Germany Series B $59.4M 2026-01-20 $69.8M Andera Partners, LBBW VC, Cure8 Ventures 1 to 10 2015
5 NVision Quantum Technologies NVision Quantum Technologies develops quantum-based imaging technology that enhances standard MRI systems. Biotech Ulm, Germany Series B $38.0M 2026-05-13 $155.2M Entrée Capital, European Commission, Playground Global +2 101 to 250 2015
6 NovaGo Therapeutics NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. Biotech Schlieren, Switzerland Series B $29.7M 2026-08-31 $39.7M Kinled Holding, Pureos Bioventures 1 to 10 2015
7 Computomics Computomics applies artificial intelligence to genomics data to advance agricultural solutions. Artificial intelligence Tübingen, Germany Series B $7.3M 2026-08-18 $10.0M HTGF (High-Tech Gruenderfonds), VentureOut, European Innovation Council +2 11 to 50 2012

Table 2. Biotech startups that raised Series B in DACH: the 7 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 HTGF (High-Tech Gruenderfonds) Venture capital firm Bonn, Germany 15 22% 1 Computomics
2 Andera Partners Private equity firm Paris, France 5 7% 1 Exciva
3 Venture Kick Startup incubator Schlieren, Switzerland 4 6%
4 VI Partners Venture capital firm Altendorf, Switzerland 4 6%
5 NRW.BANK Government investment office Düsseldorf, Germany 4 6%
6 Boehringer Ingelheim Venture Fund Corporate venture arm Ingelheim Am Rhein, Germany 4 6%
7 EQT Life Sciences Private equity firm Amsterdam, The Netherlands 4 6%
8 BioMedPartners Venture capital firm Basel, Switzerland 4 6%
9 European Innovation Council Startup accelerator Brussels, Belgium 3 4% 2 Computomics, Orbem
10 German Federal Ministry of Research, Technology and Space Government investment office Bonn, Germany 3 4% 1 NVision Quantum Technologies
11 Sofinnova Partners Venture capital firm Paris, France 3 4%
12 Forbion Capital Partners Private equity firm Naarden, The Netherlands 3 4%
13 Innosuisse Government investment office Berne, Switzerland 3 4%
14 Versant Ventures Venture capital firm Menlo Park, United States 3 4%
15 KfW Government investment office Frankfurt, Germany 3 4%

Table 3. Biotech startups that raised Series B in DACH: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 53 79% $2.1B
Software 6 9% $175.5M
Artificial intelligence 3 4% $171.2M
Hardware 1 1% $106.5M
Education 1 1%

Table 4. Biotech startups that raised Series B in DACH by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series B 67 100% $21.4M

Table 5. Biotech startups that raised Series B in DACH by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
Germany 35 52%
Switzerland 31 46%
Austria 1 1%

Table 6. Biotech startups that raised Series B in DACH by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Basel 7 10%
Munich 5 7%
Geneva 5 7%
Schlieren 4 6%
Lausanne 3 4%
Heidelberg 2 3%
Aachen 2 3%
Martinsried 2 3%
Berlin 2 3%
Bielefeld 2 3%
Zug 2 3%
Tübingen 1 1%

Table 7. Biotech startups that raised Series B in DACH by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
August 2026 3 38% $189.0M
June 2026 1 12% $50.0M
May 2026 2 25% $203.0M
January 2026 2 25% $124.1M

Table 8. Biotech startups that raised Series B in DACH: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 8 12% $566.0M
2025 4 6% $231.3M
2024 6 9% $370.5M
2023 1 1% $11.0M
2022 3 4% $86.3M
2021 6 9% $285.7M

Table 9. Biotech startups that raised Series B in DACH by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 1 1%
2020 to 2022 3 4%
2015 to 2019 19 28%
2010 to 2014 17 25%
Before 2010 27 40%

Table 10. Biotech startups that raised Series B in DACH by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 19 28%
11 to 50 31 46%
51 to 100 10 15%
101 to 250 5 7%
1,001 to 5,000 1 1%
10,001 or more 1 1%

Table 11. Biotech startups that raised Series B in DACH by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in DACH whose last round is Series B are on the list?
67, in the file dated 16 November 2026. 8 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 67 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series B in DACH: 67 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in DACH

Other sectors that raised Series B in DACH

Cite: FundingWatcher, 67 biotech companies in DACH whose most recent round is Series B, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-b/dach/